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Abstract
Background: The genetic mutation resulting in osteogenesis imperfecta (OI) type V was recently characterised as a
single point mutation (c.-14C > T) in the 5’ untranslated region (UTR) of IFITM5, a gene encoding a transmembrane
protein with expression restricted to skeletal tissue. This mutation creates an alternative start codon and has been
shown in a eukaryotic cell line to result in a longer variant of IFITM5, but its expression has not previously been
demonstrated in bone from a patient with OI type V.
Methods: Sanger sequencing of the IFITM5 5’ UTR was performed in our cohort of subjects with a clinical diagnosis
of OI type V. Clinical data was collated from referring clinicians. RNA was extracted from a bone sample from one
patient and Sanger sequenced to determine expression of wild-type and mutant IFITM5.
Results: All nine subjects with OI type V were heterozygous for the c.-14C > T IFITM5 mutation. Clinically, there was
heterogeneity in phenotype, particularly in the manifestation of bone fragility amongst subjects. Both wild-type and
mutant IFITM5 mRNA transcripts were present in bone.
Conclusions: The c.-14C > T IFITM5 mutation does not result in an RNA-null allele but is expressed in bone. Individuals
with identical mutations in IFITM5 have highly variable phenotypic expression, even within the same family.
Keywords: Osteogenesis imperfecta, Interferon-induced transmembrane protein 5 (IFITM5), Bone-restricted
interferon-induced transmembrane protein-like protein (BRIL), Hyperplastic callus, Radial head dislocation
Background
Osteogenesis imperfecta (OI) is a heterogeneous group
of disorders characterised by fragile bones. An associ-
ation of OI with hyperplastic callus was first reported by
Battle and Shattock in 1908 [1], and other papers over
the past century highlighted familial occurrence [1-3]. A
further association with calcification/ossification of the
interosseous membranes limiting pronation/supination
of the forearms was also recognized [2-5]. Further confirm-
ation that this might be a distinct genetic entity was pro-
vided by Glorieux et al. in 2000 who noted a distinctive
histomorphometric pattern in iliac crest bone biopsies [4].
OI type V is an autosomal dominant disorder occurring
either de novo or by inheritance from an affected parent.
Although its most conspicuous feature is the propensity
to form hyperplastic callus, not all patients develop this
feature [4-8]. However, when hyperplastic callus does
occur, historic reports indicate it may be so exuberant as
to lead to major functional complications – in some cases
it has resulted in amputation when it has been misdiag-
nosed as an aggressive malignancy [2].
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Through whole exome sequencing, two groups recently
identified a single point mutation (c.-14C >T) in the 5’ un-
translated region (UTR) of the gene encoding interferon-
induced transmembrane protein 5 (IFITM5, also known as
Bril) as the cause of OI type V (GenBank ID rs373183215)
[9,10]. This mutation creates a novel upstream start codon
in-frame with the wild-type IFITM5 open reading frame,
predicted to add five amino acid residues (Met-Ala-Leu-
Glu-Pro) to the encoded protein. In vitro experiments dem-
onstrated that eukaryotic cells initiated transcription from
this alternative start codon [9,10]. However, it is not known
whether the mutant allele is transcribed in human bone.
Expression of wild-type IFITM5 is restricted to bone and
cartilage [9,11], hence its alternative name Bone-restricted
interferon-induced transmembrane protein-like protein
(BRIL) [11]. However, little is known about the mechanism
of action of IFITM5 and thus how the mutation contrib-
utes to the OI type V phenotype is also unclear.
We investigated our cohort of OI type V subjects for
mutations in IFITM5. We also examined bone tissue
from an individual with OI type V for expression of mu-
tant transcripts, which has not been reported previously.
Methods
Individuals with OI type V and their families were re-
cruited from Australia and abroad through the Australian
Bone Dysplasia Registry at the University of Queensland.
Clinical information was provided by the contributing cli-
nicians. All recruited individuals or their legal guardians
gave written consent for genetic testing and de-identified
information to be published. The study was approved by
the University of Queensland Ethics Committee (HREC
reference number UQ #2011000876).
Genomic DNA was obtained from all individuals from
either blood or saliva by standard techniques, either by
a chloroform extraction method or the Oragene Self-
collection kit (Genotek, Canada). A bone sample was ob-
tained from patient 176.3 during femoral intramedullary
rod replacement surgery. RNA was extracted from bone
using TRIzol Reagent (Invitrogen, USA). cDNA was syn-
thesized using the Bioline cDNA Synthesis kit (Bioline,
UK). PCR amplification and Sanger sequencing of exon 1
(including the 5’ UTR) was performed using previously
described primers [9]. Primer sequences used for cDNA
amplification were F 5′-ACCAGTCTGAGTGTGGAAG
A-3′ and R 5′-CTGAACACCGACCAGATCAA-3′. Se-
quencing was performed on the GeneticAnalyzer 3130
(Applied Biosystems, USA) using BigDye v3.1 reagents,
and analysed using the manufacturer’s software.
Results and discussion
Nine cases with OI type V were recruited. Their clinical
details are summarised in Table 1. Individuals 185.3 and
185.4 were an affected mother and son, respectively.
One further individual (91.3) possibly had an affected par-
ent but this was not definitively confirmed. Additional
unaffected family members were recruited for individ-
uals 73.3, 88.3 and 176.3.
All subjects displayed the characteristic elbow deform-
ity with radial head dislocation - indeed, the diagnosis of
OI type V in 185.3 was only made when it was noted
that she had the same characteristic elbow deformity as
her affected son (185.4) as she had never clinically frac-
tured. In the six cases with a recorded age at which the
elbow deformity was first noted, it was present before
diagnosis of OI type V, but had been noted before the
first fracture in only two of the six subjects. Calcification
of the forearm interosseous membrane was evident in all
subjects. Five subjects developed hyperplastic callus. In
contrast, bone fragility was quite variable, evidenced by
the number of clinical fractures reported. For example,
individual 182.3, aged eight years, reported approximately
35 clinical fractures; in contrast, individual 185.3, aged
32 years, had never had a clinical fracture. Heterogeneity
was also seen in height and physical activity level. None of
the subjects had blue sclerae or opalescent dentine.
Sanger sequencing of IFITM5 showed that all individ-
uals with OI type V were heterozygous for the autosomal
dominant c.-14C > T mutation recently identified as the
cause of this disease [9,10]. The mutation segregated
with phenotype in the three families in whom unaffected
members were available.
The bone sample from individual 176.3 was analysed
for expression of wild-type and mutant IFITM5 mRNA.
Sanger sequencing of synthesized cDNA confirmed the
presence of both wild-type and mutant transcripts in the
sample (shown in Figure 1). This is the first demonstra-
tion that mutant IFITM5 is expressed in human bone.
Our data supports the current literature that IFITM5
mutation c.-14C > T is the cause of OI type V. All af-
fected individuals in our cohort were heterozygous for
this mutation. The mutation occurred de novo in the three
simplex cases for whom parental DNA was available. Cho
et al. and Semler et al. demonstrated this mutation in their
cohorts of 19 and two individuals with OI type V respect-
ively. Four other groups have subsequently found the same
mutation in their entire cohorts [12-15]. Including our co-
hort, all 95 individuals with OI type V described in the lit-
erature who have been investigated for this mutation have
been heterozygous for this mutation. Such conservation of
a single disease-causing mutation across geographically
distinct cohorts is unusual although a similar example
in skeletal disease is the 617G > A mutation in the acti-
vin A type I receptor gene (ACVR1) in fibrodysplasia
ossificans progressive, another disease with abnormal
ossification [16].
Whilst not present in all affected individuals reported to
date [17], ossification of non-skeletal tissue (in particular,
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Table 1 Clinical data of individuals with OI type V
Individual Age
(years)
Sex Age at first
fracture
Number of
clinical
fractures
Age at which
elbow deformity
noted
Age at
diagnosis
of OI
Age at
diagnosis of
OI type V
Forearm interosseous
membrane calcification
and radial head
dislocation
Hyperplastic
callus
Height
(Z-score)
Baseline BMD* Physical activity
73.3 10 F Birth ~18 1 month Birth 5 years Present Present −2.37 TB −2.69, LS −4.87
at 14 months
Walking unaided
88.3 11 M Birth >20 4 years Birth 4 years Present Present 0.359 TB −3 at
10 years
Walking unaided
91.3 25 F 3 years ~8 <1 year 9 years 9 years Present Absent −1.171 TB −2.90, LS −2.73
at 6 years
NA
150.3 61 M 6 weeks >15 30 years 6 weeks 60 years Present Absent −10.69 NA NA
176.3 14 F <12 months ~20 NA 13 months 12 years Present Present −3.94 NA Wheelchair to mobilise
181.3 7 M <11 months 20-30 NA 13 months 7 years Present Present −1.07 LS −7.8 at
13 months
Walking for 45 min
182.3 8 F <1 year ~35 4 years 2 years 8 years Present Present −3.0 LS −4.7 at 2 years Walking for
30 min intervals
185.3 32 F Never clinically
fractured
0 1 month 31 years 31 years Present Absent −2.79 NA Walking unaided
185.4 5 M 2 years 3 2.5 years 4 years 4 years Present Absent −1.10 NA Walking unaided
NA = Not available.
*Baseline BMD prior to bisphosphonate therapy expressed as z-score for total body (TB) and/or lumbar spine (LS) taken at the stated age.
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the forearm interosseous membrane) appears to be one of
the most characteristic features of this bone disease and
was present in all our subjects. An abnormal appearance
of the elbow from radial head dislocation may also be an
early and characteristic deformity and was also evident in
our entire cohort. Published case series report 76-100% of
affected individuals have calcification of the interosseous
membrane [4,6,8,9,12,13], and 36-88% have radial head
dislocation [4,8,9,13]. Conversely, a series of 489 upper
limb radiographs from individuals with OI found 86% of
those with type V had radial head malalignment compared
with 0 to 29% of those with other OI types [18]. In our co-
hort, five individuals (56%) had a history of hyperplastic
callus; previous case series report 8-65% develop this fea-
ture [4-6,8,12,13].
Bone fragility appears to be more variable. Most strik-
ingly, one adult patient had no history of clinical fracture.
The cohort reported by Cho and colleagues also included
individuals with few fractures [9]. Possibly, individuals
with a milder OI type V phenotype without a marked frac-
ture history may have been missed, skewing the current
understanding of the severity of the disorder. Height
[12,13] and bone mineral density (BMD) [12] have also
been shown to vary widely; our own data were difficult to
interpret in this regard due to bisphosphonate use and
varying methods of BMD measurement.
Classification of individuals with OI has become in-
creasingly complex, as the molecular basis of various
forms of OI has been elucidated [19-22]. Sequencing of
individuals with OI to determine their causative muta-
tion is currently a research rather than clinical tool, but
efficient and accurate sequencing may soon become rou-
tine clinical activity and facilitate a wider appreciation of
the pathogenesis of bone fragility. OI has been generally
considered a disorder of collagen or collagen processing
[21,22]; where OI type V best fits in this understanding
will become clearer as our knowledge of IFITM5 func-
tion increases. With respect to this point, it is quite sur-
prising that the phenotypes of individuals identified with
the same c.-14C > T mutation vary so significantly in their
bone fragility yet so uniformly manifest the elbow de-
formity and calcification of the forearm interosseous
membrane. Presumably other factors interacting with
IFITM5 govern the diversity of disease presentation.
Phenotypic variability in individuals carrying the same
mutation is not in itself is unique to OI type V but has
been observed with other forms of OI, possibly due to
the effect of modifier genes [23].
We have shown that the mutant form of IFITM5 is tran-
scribed into mRNA in bone, and this mutation therefore
does not result in an RNA-null allele. This has not previ-
ously been demonstrated. Unfortunately, accurate quanti-
fication of mRNA transcripts could not be performed, as
this would require large volumes of bone sample from af-
fected cases. The c.-14C > T mutation has been demon-
strated to produce a premature start codon that results in
a mutant form of IFITM5 five amino acids longer than the
wild-type in in vitro studies using HEK293T cells [9,10].
Whilst we have shown the mutant IFITM5 gene is tran-
scribed in human bone, the longer form of IFITM5 pro-
tein has not yet been demonstrated in bone; this will be
challenging in human bone due to scarcity of clinical
sample.
IFITM5 is a small transmembrane protein, with ex-
pression restricted to skeletal tissue, particularly to areas
undergoing early ossification [11,24]. In both osteoblast
cell lines and primary cultures, IFITM5 expression is
tightly correlated with differentiation and mineralisation
with highest expression in the early mineralisation stage
[11,24]. Ifitm5 overexpression in osteoblast cell lines
enhanced mineralisation and conversely decreased min-
eralisation was seen with shRNA knockdown of Ifitm5
[11]. Thus, IFITM5 appears to be an osteoblast-specific
membrane protein involved in early bone mineralisation
whose interaction partners are as yet unidentified. It is
interesting to speculate that the role of IFITM5 in min-
eralisation might contribute significantly to the ectopic
ossification and hyperplastic callus seen in individuals
with OI type V.
Surprisingly, Ifitm5-null mice did not have significantly
different morphometric parameters of the tibia compared
with heterozygous littermates [24]. Semler et al. reported
two individuals with genomic deletions resulting in hap-
loinsufficiency of IFITM5 (in addition to deletion of other
genes), both of whom had skeletal manifestations (short
stature; microcephaly, short phalanges and clinodactyly)
but not the phenotype of OI type V [10]. These studies
suggest that the clinical phenotype of OI type V is not due
to a loss of function of IFITM5. Our expression data are
consistent with this suggestion and support the premise
that OI type V is likely to arise from a gain of function of
this mutation.
A recent study suggested IFITM5 expression may be
regulated by natural antisense transcripts [25]. Whilst our
Figure 1 Sanger sequencing of cDNA from bone of individual
176.3, showing expression of both wild-type and mutant
transcripts 14 bases upstream of the start codon (arrow).
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data show both mutant and wild-type IFITM5 are ex-
pressed in bone, the relative amounts of each transcript
could not be accurately quantified. However, as the anti-
sense transcripts identified by Liu et al. were complemen-
tary to nucleotides distant to the 5’ UTR, it seems unlikely
that this mechanism of gene regulation would be affected
by the c.-14C > T mutation.
Conclusions
Our data support the hypothesis that the phenotype of
OI type V results specifically from expression of a mutant,
longer form of IFITM5 by osteoblasts. However, despite
a shared aetiology, bone fragility of affected individuals
is highly variable though almost all affected individuals
manifest interosseous membrane ossification with re-
sultant elbow deformity. Further work is needed to elu-
cidate the role of IFITM5 in osteoblast differentiation
and matrix mineralisation to understand the mechanism
by which the c.-14C > T mutation results in OI type V.
Furthermore, the elucidation of the mechanism resulting
in “explosive” hyperplastic callus formation may lead to a
specific pharmacological intervention to prevent progres-
sion of this devastating manifestation. In addition, given
the transmembrane location of IFITM5 it may be a poten-
tial therapeutic target for other bone disorders such as
fibrodysplasia ossificans progressiva and other forms of
ectopic ossification.
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